The first two authors contributed equally to this article Osteosarcoma is the most common primary malignant tumour of the bone. Although new therapies continue to be reported, osteosarcoma-related morbidity and mortality remain high. Modern medicine has greatly increased knowledge of the physiopathology of this neoplasm. Novel targets for drug development may be identified through an understanding of the normal molecular processes that are deeply modified in pathological conditions. The aim of the present study is to investigate, by immunohistochemistry, the localisation of different growth factors and of the proliferative marker Ki-67 in order to determine whether these factors are involved in the transformation of osteogenic cells and in the development of human osteosarcoma. We observed a general positivity for NGF -TrKA -NT3 -TrKC -VEGF in the cytoplasm of neoplastic cells and a strong expression for NT4 in the nuclear compartment. TGF-p was strongly expressed in the extracellular matrix and vascular endothelium. BDNF and TrKB showed a strong immunolabeling in the extracellular matrix. Ki-67/MIB-l was moderately expressed in the nucleus of neoplastic cells. We believe that these growth factors may be considered potential therapeutic targets in the treatment of osteosarcoma, although proof of this hypothesis requires further investigation.
related morbidity and mortality remain high. The survival of patients affected by osteosarcoma is conditioned by metastases. Metastatic tumours are often not responsive or only partially responsive to current therapeutic strategies and are the primary cause of cancer-related mortality. Little is known about the molecular mechanisms that control the pathogenesis of osteosarcoma. There is evidence that the course of this disease may be influenced by the presence of various proteins which play a key-role in proliferation, chemo-resistance and angiogenesis (2) . Angiogenesis, the sprouting of new capillaries from pre-existing blood vessels, is a regulated process essential in reproduction, development and tissue repair (3) . It is known that angiogenesis is an essential component in cancer development, supplying the tumour with nutrients, oxygen and growth factors as well as for metastatic spreading. A more extensive angiogenic response may indicate a very aggressive tumour with a less favourable prognosis and quantification of this characteristic could provide an indication of tumour behaviour. Angiogenesis is induced by a variety of growth factors, but the most important factor of angiogenesis is the vascular endothelial growth factor (VEGF). VEGF, also known as vascular permeability factor, existing in different isoforms which are generated by alternative splicing of a single gene (4) . Although the different isoforms seem to express identical biological activities, only the two smaller forms (VEGFI21 and VEGFI65) are secreted in soluble form, whereas the larger ones remain cellassociated (5) . The expression of VEGF is a signal of the tyrosine kinase cascade activation initiated by binding VEGF to the VEGF receptor (VEGFR). As a result of this process, new vessel formation around the tumor is initiated (6) . Prostaglandins (PGEl and PGE2), potent stimulators of bone formation, and other growth factors rapidly induce VEGF expression in osteoblasts (7) . The transforming growth factor ps (TGF-ps) are a family of multifunctional cell peptides that regulate cell growth, differentiation, and extracellular matrix production. Three Transforming growth factor-B (TGF-P) isoforms have been identified in human tissues and bone matrix. Previous studies showed that TGF-p was localized in osteoblasts and osteoclasts of fetal bones from different species (8) . TGF-p 1 is released by the osteoblasts in the extracellular matrix in a latent form and may be activated by the osteoclasts during the resorptive phase (9) . The active molecule may also influence bone resorption by inhibiting the formation of new osteoclasts from their precursors and decreasing the activity of mature osteoclasts (10) . In a previous study, employing osteosarcoma cell lines, Kloen et al. (11) were able to demonstrate that these neoplastic cells produce TGF-p that stimulates their own proliferation, suggesting that an autocrine loop involving TGF-p may contribute to the growth of human osteosarcomas. Another study showed that high-grade osteosarcomas had a significantly higher expression of I'Gf-Bl than lowgrade osteosarcomas, while levels of TGF-p2 and TGF-p3 were comparable in the two groups (12) . There are no data in the literature on the expression of neurotrophins in osteosarcoma cell lines. Neurotrophins (NTs), also known as neurotrophic factors, constitute a family of dimeric proteins working as polypeptidic growth factors, which include nerve growth factor (NGF), brain derived growth factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6, the last being apparently specific for fish (13) . Biological actions of NTs are mediated by the binding with two families of membrane receptors, the high-affinity tyrosine kinase (Trk) and the low-affinity p75 (p75NT receptor) receptors (14) . The Trk family includes TrkA, TrkB and TrkC receptors, whereas p75NT receptor belongs to the trans-membrane molecules serving as receptor for tumor necrosis factor and cytokines (15) . TrkA is specifically activated by NGF, whereas TrkB and TrkC are primarily receptors for BDNF and NT-3 respectively (16, 17) . NTs are involved in vertebrate neuronal cell development, differentiation, survival and functional activities. NTs are also involved in the modulation ofadult central nervous system functions and organization, as well as in the vegetative innervation of several organs (16) . Moreover, detailed studies have revealed significant actions of neurotrophins in a wide variety of tissues outside the nervous system, especially in the immune system (18) . All these findings prompted us to investigate the localization and intracellular distribution of the above-mentioned growth factors and their relative receptors, to determine whether these growth factors are involved in the insorgence and development of human osteosarcoma. In the present study we also investigated the expression of VEGF, PGE2, TGF-~and neurotrophins by immunohistochemical and immunofluorescence techniques in some tissue samples of osteosarcoma not otherwise specified (NOS) and osteosarcoma cell lines: the aim of this investigation is to elucidate the role of these proteins in osteosarcoma carcinogenesis. Ki-67, a nuclear antigen that has proved to be useful in assessing several tumors, provides information about cell proliferation and, consequently, long-term prognosis (19) . Hence, we decided to investigate, together with the analysis of the growth factors pattern, the expression level ofKi67 to define its possible role as a prognostic factor in osteosarcoma. The identification of these growth factors is crucial for understanding tumor dissemination and for the development of novel therapies
MATERIALS AND METHODS

Study population
The population of this study included 50 formalinfixed, paraffin-embedded blocks of surgical osteosarcoma specimens obtained from the Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, l.CO.T, Latina, Italy. The osteosarcoma specimens were harvested from 50 patients with osteosarcoma not otherwise specified (NOS) aged 10-38 years. During excision, apart from anaesthesia, no other chemical product or pharmaceutical drug had been administered. Core tissue biopsies of 1 mm in diameter were taken from representative regions of each paraffin-embedded tumor (donor block) and arrayed into a new recipient paraffin block (45 mm x 20 mm) using the ATA-l00 Chemicon International System. To minimize the influence of tumor and tissue heterogeneity, three different core biopsies for each donor block were harvested. Each array contained 50 tissue cylinders. Experiments were performed in compliance with the Italian laws and guidelines concerning the patients' written informed consent. The ethics committee of the Hospital Policlinico Umberto I approved our study according to the European Community and Italian laws.
Cell culture
Human osteosarcoma cell lines (SaOS-2, MG-63, 143 PML BK TK and HS888.T) were grown under subconfluent or confluent conditions in medium, at 37°C with 5% of CO 2 , Saos-2 is a non-transformed cell line derived from the primary osteosarcoma of an ll-year-old Caucasian female (osteogenic sarcoma). MG-63 is a cell line derived from an osteosarcoma of a 14-year-old Caucasian male (high yields of interferon). 143 PML BK TK is a cell line derived from primary osteosarcoma of a 13-year-old Caucasian female (adherent cells with fibroblastic morphology). Hs888.T is a cell line derived from osteosarcoma of a 20-year-old Caucasian male (adherent cells with mixed morphology). Cells were cultured in Dulbecco's minimum essential medium (Sigma) supplemented with 10% fetal bovine serum (GIBCO) with penicillin (LOuug/ml), streptomycin (lOOD/ml) and sodium pyruvate. Cells were cultured on cover glass for immunofluorescence analysis and were fixed with 3% parafonnaldehyde/phosphatase-buffered saline.
Immunohistochemical analysis
The method employed for immunohistochemical tests was ABC/HRP technique (avidin complexed with biotinylated peroxidase). Serial 3-llm thick sections were cut using a rotative microtome, mounted on gelatincoated slides and processed for immunohistochemistry. These sections were deparaffinized in xylene and dehydrated. They were immersed in citrate buffer (pH 6) and subjected to microwave irradiation twice for 5 min each time. Subsequently, all sections were treated for 30 min with 0.3% hydrogen peroxide in methanol to quench endogenous peroxidase activity. To block nonspecific binding, the slides were incubated in 3% nonnal goat serum in PBS for 30 min at room temperature. In order to study the immunolocalization of neurotrophins and their own receptors, the following antibodies were used: i) rabbit anti-NGF polyclonal antibody (Santa Cruz Biotechnology, CA, USA; ii) rabbit anti-BDNF polyclonal antibody (Santa Cruz Biotechnology, CA, USA); iii) rabbit anti-NT3 polyclonal antibody (Santa Cruz Biotechnology;) iv) rabbit anti-NT4 polyclonal antibody (Santa Cruz Biotechnology); v) rabbit anti-TrKA polyclonal antibody (Santa Cruz Biotechnology); vi) rabbit anti-TrKB polyclonal antibody (Santa Cruz Biotechnology); vii) rabbit anti-TrKC polyclonal antibody (Santa Cruz Biotechnology); viii) mouse anti-VEGF monoclonal antibody (Abeam Cambridge Science Park, UK); ix) mouse anti-TGf-Bl monoclonal antibody (Abeam Cambridge Science Park, UK); x) rabbit anti-PGE2 polyclonal antibody (Abeam Cambridge Science Park, UK); xi) rabbit anti-ki-67 polyclonal antibody (Santa Cruz Biotechnology). Incubation with primary antibodies was performed overnight at 4°C at a final concentration of2-5 ug/ml, Optimal antisera dilutions and incubation times were assessed in a series of preliminary experiments. After exposure to the primary antibodies, slides were rinsed twice in phosphate buffer and incubated for I h at room temperature with the appropriate secondary biotinylated goat anti-mouse or anti-rabbit Ig-G (vector laboratories Burlingame, CA, USA, BA9200 and BA I000) and with peroxidase-conjugated avidin (Vector laboratories, Burlingame, CA, USA, Vectastain Elite ABC Kit Standard* PK 6-100) for 30 min. After a further wash with phosphate buffer, slides were treated with 0.05% 3,3-diaminobenzidine (DAB) and 0.1% H202. Finally, sections were counterstained with Mayer's hematoxylin and observed using a light microscope. Negative control experiments were carried out: i) by omitting the primary antibody; ii) by substituting the primary antibody with an equivalent amount of non-specific immunoglobulins; iii) by pre-incubating the primary antibody with the specific blocking peptide (antigen/antibody = 5 according to the supplier's instructions). The staining assessment was made by two experienced observers under light microscopy. The intensity of the immune reaction was assessed microdensitometrically using an lAS 2000 image analyzer (Delta Sistemi, Rome, Italy) connected via a TV camera to the microscope. The system was calibrated taking the background obtained in sections exposed to non-immune serum as zero. Ten I00 urrr' areas were delineated in each section by a measuring the diaphragm. Quantitative data of the intensity of the immune staining were analyzed statistically by analysis of the variance (ANOVA) followed by Duncan's multiple range test as a post hoc test.
Immunofluorescence in osteosarcoma eel/lines
Cellular cultures (SaOS, MG-63, 143 PML BK TK and HS888.T) were incubated with primary antibody and then with fluoresceinated secondary antibody. The anti-mouse Alexa Fluor 488 antibody or anti-rabbit Alexa Fluor 488 antibody (I :300) was applied for 2 h at 37°C after three washes in 0.1% Tween in PBS for 10 min each. Slides were counterstained with DAPI (Vectashield Mounting Medium with DAPI) after extensive washing with PBS. The reaction was examined by a confocal laser microscope (Nikon TE2000) for immunofluorescence analysis. Membranous, cytoplasmic, and nuclear expressions were independently assessed.
RESULTS
Immunohistochemical analysis
Sections of bone tissues taken from patients suffering from not otherwise specified osteosarcoma (NOS) exposed to the primary/ secondary antibodies, developed a dark-brown (intense), yellow-brown (slight) or no appreciable immunostaining. Immunoreactivity was specific since no immunostaining was obtained in positive control sections incubated with each primary antibody adsorbed with the specific peptide or with pre-immune serum (data not shown). Osteosarcoma is a heterogeneous group of malignant spindle cell tumors, the common feature of which is the production of immature bone which, if noncalcified, is also known as osteoid. The sections harvested from osteogenic tissues showed, in the neoplastic cells, a relevant immunoreactivity for NGF in the cytoplasmic compartment while it was absent in the nuclear compartment (Fig. IA) . TrKA immunoreactivity was significantly high in the cytoplasmic compartments of the neoplastic cells, but moderate in the extracellular space ( Fig. IB) . BDNF showed a high expression in the extracellular compartment and was moderate in the cytoplasmic compartment of neoplastic cells ( Fig. 2A) . TrKB was moderately expressed in the cytoplasmic compartment of the neoplastic cells and extracellular matrix (Fig. 2B ). NT-3 was appreciable in the cytoplasmic compartment of osteogenic tissue and weakly expressed in the extracellular space (Fig.  3A) . NT-4 showed a strong expression in the nuclear compartment ofthe neoplastic cells in the osteogenic tissue and weak in the extracellular matrix (Fig. 3B ). Immunoreactivity for TrKC was strongly present in cytoplasmic compartment of the neoplastic cells and moderate in the extracellular space (Fig. 3C) . These results showed a direct proportionality between the profiles of the expression of neurotrophins and their target receptors. Positive immunoreactivity for Ki67 was found only in the nuclear compartment of the neoplastic cells ( Fig. 4) . VEGF expression was observed not only in tumor cells but also throughout the extracellular matrix and endothelial cells of the surrounding vessels ( Fig. 5 ). TGF-p was not observed in the cytoplasmic and nuclear compartments of tumor cells but was strongly expressed in the extracellular matrix and vascular endothelium ( Fig. 6 ). VEGF was expressed more strongly within the vascular endothelial cells of the extracellular matrix than within the tumor cells. The presence of VEGF-A in osteosarcoma biopsy samples was observed with variable intensity within the cytoplasm and/or membrane of osteosarcoma cells. These data are specified in detail in Table I . The percentage values of growth factor-positive A B
Fig. 1. Immunohistochemical analysis ofspecimens of human osteosarcoma not otherwise specified for NGF (A) and TrKA (B). A) NGF immunoreactivity appears to be positive in the cytoplasmic compartment of neoplastic cells and absent in extracellular matrix and endothelial cells of vessels. B) TrKA immunoreactivity was significantly high in the cytoplasmic area ofthe neoplastic cells, but moderate in the extracellular space (20X).
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Fig. 2. Immunohistochemical analysis ofspecimens ofhuman osteosarcoma not otherwise specifiedfor BDNF (A) and TrKE (B). A) BDNF and (B) TrKE immunoreactivity appears to be moderately expressed in the cytoplasmic compartment ofneoplastic cells and strongly expressed in extracellular matrix, but totally absent in vascular endothelium (40X).
cells and P-values are shown in Table II (t-test).
Immunofluorence protein expression in cell culture
The immunofluorescence was performed on osteosarcoma cell lines as described above (SaGS, MG-63, 143 PML BK TK and HS888.T) to evaluate the level of expression and localization of VEGF, TGF-~and PGE2. All of these cell lines were positive for VEGF and PGE2 proteins (Table III) . In osteosarcoma cell lines no signal for TGF-w as observed ( Fig. 8 ). VEGF and PGE2 showed a high intensity of fluorescence, whereas only a diffuse signal was appreciable in the cytoplasmic compartment ( Fig. 7A-B area ofneoplastic cells and the total absence ofTGF-ĩ n these cells as shown by immunohistochemical studies. Results concerning the immunoreactivity for VEGF, TGF-p and PGE2 are summarized in Table  III .
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Fig. 3. Immunohistochemical analysis ofspecimens ofhuman osteosarcoma not otherwise specifiedfor NT3 (A). NT4 (B) and TrKC (C). A) NT-3 immunoreactivity appears to be appreciable in the cytoplasmic compartment ofosteogenic tissue and weak in the extracellular matrix. B) NT-4 was strongly expressed in the nuclear compartment ofthe neoplastic cells in the osteogenic tissue. C) Immunoreactivity for TrKC was appreciable in the cytoplasmic compartment ofthe neoplastic cells and moderate in the extracellular space (40X).
DISCUSSION
Osteosarcoma is the most common primary malignant bone tumour in pediatric-age patients in which the osteoid or bone is produced directly by tumor cells (20) . The prognosis of osteosarcoma patients resulted in a significant improvement after the introduction of neoadjuvant chemotherapy. Notwithstanding the advances made in the therapeutic approach to these lesions, approximately 20-30% of patients with an osteosarcoma will eventually develop a metastasis, which may cause death (21). The treatment of osteosarcoma is based on a combined approach of primary antiblastic chemotherapy and tumour surgery, followed by adjuvant chemotherapy (22) . The identification of molecular events related to tumour biology and growth is crucial for understanding tumor dissemination and for the development of a novel therapy. The course of the disease may be modified by the contribution of various proteins which play a key role in proliferation, chemoresistance and angiogenesis. Angiogenesis, which is defined as the formation of new blood vessels from existing capillaries, is a normal and vital process in the growth and development of both normal tissues and tumours. One of the most potent and specific angiogenic factors is vascular endothelial growth factor (VEGF), also known as vascular permeability factor and vasculotropin. Recent reports showed that patients with VEGF-positive osteosarcoma have lower survival rates than VEGF-negative ones (23) .
Other studies failed to show a correlation between Fig. 7 . Immunofluorescent staining of VEGF (A) and PGE2 (8) in SaDS osteosarcoma cell culture. VEGF and PGE2 were localized at cytoplasmic level of these neoplastic cells (40X). the levels of VEGF or microvascular density and survival of patients with osteosarcoma (24) . The purpose of this study was to demonstrate the strong association between a high expression ofVEGF and development of the bone tumour. Our data showed that the expression of immunoreactivity for the VEGF growth factor was higher within the vascular endothelial cells, rather than inside osteoblastic tumour cells, thus demonstrating the involvement of this vascular growth factor in the induction and regulation of pathological angiogenesis. In the future, the assessment of VEGF may be helpful both for predicting the prognosis of patients with osteosarcoma and also for indicating a particular target therapy. Prostaglandins EI-E2 (PGEI-PGE2), strong stimulators ofbone formation, rapidly induced VEGF expression in osteoblastic cells (7) . Our data showed strong cytoplasmic expression of PGE2 in human osteoblastic osteosarcoma cell lines (SaOS, MG-63, 143 PML BK TK and HS888.T) similarly to VEGF, confirming a close correlation between the expression of PGE2 and VEGF in osteosarcoma.
TGF-~is
a polypeptide with multiple physiological functions. This growth factor plays an important role in the control of the cell cycle and in the regulation of cell-cell interactions (25) . Local production of large amounts of TGF-p in the skeletal tissue combined with its pivotal role in osteoblast behaviour suggest the presence of a wellbalanced autocrine control in normal bone (26) . A (27) . The production of endogenous TGF-~may induce a direct positive autocrine growth effect in fibroblasts and osteoblasts. Our studies showed that TGF-~was not present in tumour cells, but only in the extracellular matrix and in the endothelial cells of the surrounding vessels. These results suggest that TGF-p operates not only on the growth of tumour cells, but also on the changes in local micro-environment. These data also suggest that TGF-p isoform alone is not sufficient to explain the entire aspect of metastasization and requires further studies. In view of the importance of TGF-p for controlling the growth of osteosarcoma, elucidation of the mechanisms involved in the regulation of its expression could improve our understanding of the biological behaviour of these neoplasms and playa role in the development ofnew therapeutic strategies. Ki-67, a nuclear antigen recognized by the monoclonal antibody MIB-l, was statistically elevated in higher-grade tumors and metastatic lesions, but was not influenced by tumour type or patient's sex. Significant differences in Ki-67 expression were noted among primary tumours, treated tumours and metastatic lesions: treatment resulted in a reduction of tumor proliferative activity, while tumour progression was associated with increased proliferative activity. In addition, proliferative activity was noted to be associated with tumour grade and aggressiveness (28) . In our studies Ki-67 resulted mildly detectable in tumoural cells, but totally absent in the vascular endothelium. However, the distribution and localization of this factor in human neoplastic bone cells is confirmed to be nuclear. These findings could be of clinical significance for monitoring disease progression and response to treatment with chemotherapy and radiotherapy. Neurotrophic growth factors (NGF, BDNF, NT-3 and NT-4) binding TrK receptors (TrKA, TrKB and TrKC) cause neuronal cell differentiation, proliferation and survival, thus regulating neuronal development and maintenance of neuronal networks (29) . In addition to their involvement in the nervous system, TrK receptors and neurotrophins appear to participate in homeostatic and reparative bone morphogenesis (30) as well as to play a role in some pathological processes, including tumourigenesis. Previous studies have suggested that TrkA signalling exerts antiapoptotic effects in murine and human immortalized boneforming cells. In the MC3T3-EI murine osteoblast cell line, activation of TrKA with NGF reduces apoptotic DNA breakdown in osteoblasts secondary to cytotoxic treatments (31) . In the human osteoblast cell line hFOB, the antiapoptotic effects of TrKA signalling appear to be cell-cycle dependent (32) . NGF-mediated signalling through the TrKA receptor appears to protect proliferating osteoblast cells from programmed cell death. In our observations we found a relevant immunoreactivity for neurotrophins in the cytoplasmic compartment of the human neoplastic cells similarly to their receptors, whereas a weak level was observed in the extracellular matrix. On the other hand, NT-4 showed a moderate expression in the nuclear compartment of bone neoplastic cells, suggesting the direct role of this neurotrophin in increasing the proliferation rate of the neoplastic cells. To sum up, we observed a generally relevant positive immunoreaction for NGF -TrKA -NT3 -TrKC in the cytoplasmic compartment and for NT-4 in the nucleus of tumoural bone cells, suggesting a direct role of these molecules in increasing the cell proliferation rate in the neoplastic tissue. Moreover, we found a strong expression for BONF in the extracellular space, suggesting that this factor directly influences spreading of neoplastic cells, attributable to an increase in tumor size, also due to a high vascularization network. Neurotrophins and their receptors may finally be used all together as a panel of possible diagnostic factors, to monitor the histological transformation and development of osteosarcomas.
The current antiproliferative chemotherapies used to treat patients with osteosarcoma may induce debilitating side effects, including hematological, liver, renal, cardiac, neurological and gonadal toxicity. These agents are also mutagenic and can cause secondary malignancies, most commonly leukemia, brain cancer, soft tissue sarcomas and breast cancer (32) . In conclusion, treatment regimens against specific targets such as growth factors (neurotrophins, tyrosine kinases, VEGF, PGE2 and TGF-~) are likely to produce less toxic side effects. Consequently, such targeted therapies may offer patients the hope of an improved quality of life as well as increased survival. Additional studies are, however, necessary to better explain the biological role of these molecules in the development and progression of this type of tumour.
